Test Catalog

Test ID: NPM1Q    
Nucleophosmin (NPM1) Mutation Analysis, Varies

Useful For Suggests clinical disorders or settings where the test may be helpful

As a prognostic indicator in patients with newly diagnosed acute myelogenous leukemia with normal karyotype and no FLT3 mutation and as a leukemia-specific marker of minimal residual disease

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Both DNA and RNA are extracted. The assay is composed of 2 parts, a RNA-based, sensitive quantitative reverse transcription real-time polymerase chain reaction (RT-PCR) that detects and quantifies the most common altered NPM1 mRNA transcripts (A, B, D forms) in acute myeloid leukemia (AML), and a DNA-based qualitative NPM1 exon 12 variant screen by fragment analysis that detects essentially all altered forms reported in AML, including the rare non-A, B, D forms (with lower sensitivity at the DNA level).

Special Instructions Library of PDFs including pertinent information and forms related to the test

Method Name A short description of the method used to perform the test

RNA: Reverse-Transcription Quantitative PCR (RT-qPCR)

DNA: Polymerase Chain Reaction (PCR) with Fragment Analysis by Capillary Gel Electrophoresis

NY State Available Indicates the status of NY State approval and if the test is orderable for NY State clients.


Reporting Name Lists a shorter or abbreviated version of the Published Name for a test

NPM1 Mutation Analysis, V

Aliases Lists additional common names for a test, as an aid in searching

Nucleophosmin Mutation Analysis